Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blinded, Multi-Center Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Sorafenib in Combination With AMG 386 or Placebo In Subjects With Metastatic Clear Cell Carcinoma of the Kidney

NCT00467025 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00467025
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00467025 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blinded, Multi-Center Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Sorafenib in Combination With AMG 386 or Placebo In Subjects With Metastatic Clear Cell Carcinoma of the Kidney
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2007
Completion date
June 30, 2014
Enrollment
152 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced renal cell carcinoma